Novo Nordisk
Open
$43.52
Prev. Close
$43.52
High
$43.62
Low
$43.52
Market Snapshot
$194.45B
10.3
3.26
$41.7B
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk's oral Wegovy pill has gained UK approval, becoming the first oral GLP-1 weight-loss treatment available in Europe, expanding obesity management options.
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Recently from Cashu
Novo Nordisk's CagriSema Trial Shows Promise for Diabetes Management and Expanding Treatment Focus
Novo Nordisk (Ticker: NVO) has recently achieved promising outcomes from its Phase 3 REIMAGINE trial for CagriSema, a novel combination therapy designed for the management of type 2 diabetes. The tria…
FDA Approves Novo Nordisk’s Non-Injectable GLP-1 Therapy for Weight Management
The approval by the FDA grants eligible patients a new non-injectable alternative to GLP-1-based weight-loss therapies, marking a significant advancement in obesity management. This innovative treatme…
Novo Nordisk Partners with Veru for Wegovy Trial Targeting Obesity in Older Adults
Novo Nordisk (Ticker: NVO) strengthens its position in the obesity treatment market through a strategic collaboration with Veru Inc. This partnership involves a clinical supply agreement to provide We…
Novo Nordisk Set to Present Key Data on Obesity and Diabetes Management at ADA 2026
Novo Nordisk (Ticker: NVO) prepares to unveil crucial clinical data from its cardiometabolic portfolio at the 2026 American Diabetes Association (ADA) Scientific Sessions. This gathering underscores t…